1-5 of 5
Kevin B. Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

Martin Schuler, Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow, Filip Y.F.L. De Vos, Carla M.L. van Herpen, Matteo S. Carlino, Douglas B. Johnson, Carola Berking, Micaela B. Reddy, Allison S. Harney, Jordan D. Berlin, Rodabe N. Amaria
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3002–3010.
https://doi.org/10.1158/1078-0432.CCR-21-3872
Published: 15 July 2022
View articletitled, Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Open the PDF for Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

David S. Hong, Razelle Kurzrock, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, Siqing Fu, Kevin B. Kim, Michael A. Davies, Ly M. Nguyen, Goldy C. George, Lucy Xu, Robert Shumaker, Min Ren, Jennifer Mink, Cynthia Bedell, Corina Andresen, Pallavi Sachdev, James P. O'Brien, John Nemunaitis
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (21): 4801–4810.
https://doi.org/10.1158/1078-0432.CCR-14-3063
Published: 01 November 2015
View articletitled, Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
Open the PDF for Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma in another window
Includes: Supplementary data
Journal Articles

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, H.-Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna Pavlick, Melvin T. Chin, Steven J. O'Day, Samuel C. Blackman, C. Martin Curtis, Peter Lebowitz, Bo Ma, Daniele Ouellet, Richard F. Kefford
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4449–4458.
https://doi.org/10.1158/1078-0432.CCR-14-0887
Published: 01 September 2014
View articletitled, Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
Open the PDF for Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436) in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Michael A. Davies, Patricia S. Fox, Nicholas E. Papadopoulos, Agop Y. Bedikian, Wen-Jen Hwu, Alexander J. Lazar, Victor G. Prieto, Kirk S. Culotta, Timothy L. Madden, Quanyun Xu, Sha Huang, Wanleng Deng, Chaan S. Ng, Sanjay Gupta, Wenbin Liu, Janet E. Dancey, John J. Wright, Roland L. Bassett, Patrick Hwu, Kevin B. Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1120–1128.
https://doi.org/10.1158/1078-0432.CCR-11-2436
Published: 14 February 2012
View articletitled, Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
Open the PDF for Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Kevin B. Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael M. Shi, John M. Kirkwood
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7451–7461.
https://doi.org/10.1158/1078-0432.CCR-11-1747
Published: 30 November 2011
View articletitled, Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
Open the PDF for Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma in another window
Includes: Supplementary data